Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Lutetium-177-PSMA Radioligand Therapy in Advanced Salivary Gland Cancer Patients (LUPSA)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04291300
Recruitment Status : Recruiting
First Posted : March 2, 2020
Last Update Posted : May 28, 2020
Sponsor:
Collaborator:
Dutch Cancer Society
Information provided by (Responsible Party):
Radboud University

Brief Summary:
Phase 2 pilot study, which evaluates the safety and efficacy of Lutetium-177-PSMA radioligand therapy in advanced salivary gland cancer patients.

Condition or disease Intervention/treatment Phase
Salivary Gland Cancer Salivary Duct Carcinoma Adenoid Cystic Carcinoma Drug: Lutetium-177-PSMA-I&T Phase 2

Detailed Description:

Rationale: Prostate specific membrane antigen (PSMA) is a transmembrane protein, which is expressed on prostate cancers cells and other malignancies. Recently, several ligands have been developed that target PSMA. Linked to Gallium-68, this enables diagnostic 68Ga-PSMA-PET/CT scans. Linked to Lutetium-177 enables therapeutic 177Lu-PSMA Radioligand therapy. Most research on the diagnostic and therapeutic possibilities of PSMA has been conducted in patients with advanced prostate cancer.

This research group investigates whether these findings also apply to salivary gland cancer (SGC), a rare cancer. Previously the investigators conducted a phase II 68Ga-PSMA imaging study (NCT03319641), to evaluate PSMA ligand uptake in locally advanced, recurrent and metastatic (R/M) ACC and SDC (two subtypes of SGC). A relevant PSMA-ligand uptake was observed in 93% of ACC patients and 40% of SDC patients. Therefore we consider 177Lu-PSMA radioligand therapy a potential new treatment option for these subtypes of SGC.

Objective: To evaluate the safety and efficacy of 177Lu-PSMA RLT in patients with R/M ACC and SDC with PSMA ligand uptake.

Study design: Phase II pilot study, single centre, two cohorts.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 10 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Intervention Model Description: Phase II pilot study, single centre, two cohorts. Cohort 1: Patients with R/M ACC, Cohort 2: Patients with R/M SDC
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Lutetium-177-PSMA Radioligand Therapy for Advanced Salivary Gland Cancer, a Phase II Pilot Study.
Actual Study Start Date : May 26, 2020
Estimated Primary Completion Date : May 26, 2022
Estimated Study Completion Date : May 1, 2024

Resource links provided by the National Library of Medicine

Drug Information available for: Lutetium

Arm Intervention/treatment
Experimental: Lutetium treatment
Drug: Lutetium-177-PSMA-I&T, 4 cycles of 7.4 GBq intravenously, every 6 weeks.
Drug: Lutetium-177-PSMA-I&T
4 cycles of 7.4 GBq 177Lu-PSMA every 6 weeks.
Other Name: Lutetium-177 Prostate Specific Membrane Antigen




Primary Outcome Measures :
  1. Adverse events measured using Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 [ Time Frame: Through study completion, up until 3 years after last patient commences treatment ]
    Safety


Secondary Outcome Measures :
  1. Objective response rate (ORR) [ Time Frame: Through study completion, up until 3 years after last patient commences treatment ]
    Response will be measured according to RECIST version 1.1

  2. Progression free survival (PFS) [ Time Frame: Through study completion, up until 3 years after last patient commences treatment ]
    PFS will be defined as time from study enrollment until disease progression or death.

  3. Overall survival (OS) [ Time Frame: Through study completion, up until 3 years after last patient commences treatment ]
    OS will be defined as time from study enrollment until date of death of any cause.

  4. Duration of response (DoR) [ Time Frame: Through study completion, up until 3 years after last patient commences treatment ]
    Only patients with complete remission or partial response will be included in the assessment of DoR. DoR is defined as time from study enrollment until disease progression or death

  5. Quality of life (QoL) [ Time Frame: Trough study completion, up until 3 years after last patient commences treatment ]
    QoL will be assessed using EORTC QLQ-C30 questionnaire. This is the core questionnaire for assessing health related quality of life of cancer patients participating in clinical trials. It contains 30 items and incorporates a global health status scale, five functional scales, three symptom scales, and several single items assessing additional symptoms. All of the scales and single-item measures range from 0-100. A high score for global health status represents a high QoL, a high score in functional scale represents a high/healthy level of functioning, a high score for a symptom scale/item represents a high level of symptomatology/problems.

  6. Quality of life (QoL) [ Time Frame: Trough study completion, up until 3 years after last patient commences treatment ]
    QoL will be assessed using EORTC QLQ-H&N43 questionnaire. This is an additional questionnaire to assess health related topics relevant for head and neck cancer patients. The module contains 43 questions, all symtom scales or symptom items.All of the scale/item measures range from 0-100. For all scales/items higher scores indicate more problems.

  7. Quality of life (QoL) [ Time Frame: Trough study completion, up until 3 years after last patient commences treatment ]
    QoL will be assessed using performance status scale for head&neck cancer patients (PSS-HN). It contains 3 items, each randing from 0-100. These items are rated by the health professional. A high score indicates a high performance status.

  8. Quality of life (QoL) [ Time Frame: Trough study completion, up until 3 years after last patient commences treatment ]
    QoL will be assessed using pain visual analogue scale (VAS) questionnaire. This include two questions: the average pain during the past week and the worst pain during the past week. Both questions range from 0-100, a higher score indicates more pain.

  9. Dosimetry [ Time Frame: From start of study till last patient commences last SPECT/CT (7 days after first treatment cycle) ]
    Delivered doses will be calculated based on pharmacokinetics in the blood and dosimetry on SPECT/CT imaging.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients must have the ability to provide written informed consent.
  • Patients must be ≥ 18 years of age.
  • Patients must have an ECOG performance status of 0 to 2.
  • Patients must have histological, pathological, and/or cytological confirmation of either adenoid cystic carcinoma or salivary duct carcinoma.
  • Patients must have incurable, local or regional recurrent or metastatic ACC or SDC.
  • Patients with ACC can only participate in case of objective growth in the last three months or complaints due to the disease.
  • Patients must have adequate organ function:

    • Sufficient bone marrow capacity as defined by: WBC count (white blood cell) ≥2.5x10^9/L, PLT (platelet) count ≥100x10^9/L, Hb ≥6 mmol/L, absolute neutrophil count (ANC) ≥1.5x10^9/L
    • Adequate liver function as defined by:Total bilirubin ≤1.5 x ULN. For patients known with Gilbert's Syndrome ≤ 3 x ULN is permitted. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤3.0 × ULN OR ≤5.0 × ULN for patients with liver metastases.
    • Adequate kidney function as defined by:serum creatinine ≤1.5 x ULN or creatinine clearance ≥ 50 mL/min
  • Patients must have measurable disease at baseline. Defined as ≥ 1 lesion ≥ 2 cm (long axis) that is present on baseline CT.
  • Patients must have a positive 68Ga-PSMA PET/CT scan, defined by at least one lesion ≥ 1.5 cm (long axis) with a ligand uptake above liver level.

Exclusion Criteria:

  • Patients whom are pregnant or breast feeding.
  • Patients with reproductive potential not implementing adequate contraceptives measures.
  • Patients with known brain metastases or cranial epidural disease or intracardial metastases.
  • Patients with concurrent serious (as determined by the Principal Investigator) medical conditions, including, but not limited to, New York Heart Association class III or IV congestive heart failure, history of congenital prolonged QT syndrome, uncontrolled infection, active hepatitis B or C, or other significant co-morbid conditions that in the opinion of the investigator would impair study participation or cooperation.
  • Patients with urinary tract obstruction or marked hydronephrosis
  • Less than 4 weeks since last myelosuppressive therapy or other radionuclide therapy.
  • Concomitant cancer treatments

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04291300


Locations
Layout table for location information
Netherlands
Radboudumc Recruiting
Nijmegen, Gelderland, Netherlands, 6500HB
Contact: Carla ML van Herpen, MD, PhD    +31243613457    Carla.vanHerpen@radboudumc.nl   
Principal Investigator: Carla ML van Herpen, MD, PhD         
Sub-Investigator: Martin Gotthardt, MD, PhD         
Sub-Investigator: James Nagarajah, MD, PhD         
Sub-Investigator: Maike JM Uijen, MD         
Sponsors and Collaborators
Radboud University
Dutch Cancer Society
Layout table for additonal information
Responsible Party: Radboud University
ClinicalTrials.gov Identifier: NCT04291300    
Other Study ID Numbers: MOHN18
First Posted: March 2, 2020    Key Record Dates
Last Update Posted: May 28, 2020
Last Verified: February 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Carcinoma
Salivary Gland Neoplasms
Carcinoma, Adenoid Cystic
Carcinoma, Ductal
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Mouth Neoplasms
Head and Neck Neoplasms
Neoplasms by Site
Mouth Diseases
Stomatognathic Diseases
Salivary Gland Diseases
Adenocarcinoma
Neoplasms, Ductal, Lobular, and Medullary